GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA. Health Canada has previously granted approval to initiate this Phase 2 ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

Learn how Aimovig for migraine works, how well it works, what to know before starting, and its possible side effects. Experts and community members also weigh in about their experiences with Aimovig.

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

Dr Bahl said ICMR will support the development of newer therapies such as gene therapy and help take them to the market.

The pharmaceutical landscape is undergoing a dramatic transformation. New modalities are reshaping what's possible in drug development, from monoclonal antibodies to RNA therapies, from small ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...